{
    "id": 353,
    "fullName": "KRAS mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KRAS mutant indicates an unspecified mutation in the KRAS gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 3845,
        "geneSymbol": "KRAS",
        "terms": [
            "KRAS",
            "'C-K-RAS",
            "C-K-RAS",
            "c-Ki-ras",
            "c-Ki-ras2",
            "CFC2",
            "K-Ras",
            "K-Ras 2",
            "K-RAS2A",
            "K-RAS2B",
            "K-RAS4A",
            "K-RAS4B",
            "KI-RAS",
            "KRAS1",
            "KRAS2",
            "NS",
            "NS3",
            "OES",
            "RALD",
            "RASK2"
        ]
    },
    "variant": "mutant",
    "createDate": "03/13/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10893,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5674,
                "therapyName": "Irinotecan + Reolysin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8908,
                    "pubMedId": 24798549,
                    "title": "Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24798549"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2732,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Panulisib (P7170) demonstrated inhibition of tumor growth in cell line xenograft models of non-small cell lung cancer harboring KRAS mutations (Cancer Res 2012, 72(8 Suppl), Abstract #3759).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 857,
                "therapyName": "Panulisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1087,
                    "pubMedId": null,
                    "title": "Abstract 3759: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic option for Kras mutated non small cell lung cancer (NSCLC)",
                    "url": "http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/3759"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19934,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of  borussertib and Mekinist (trametinib) inhibited tumor growth in KRAS-mutant colorectal carcinoma patient-derived xenograft (PDX) models, resulting in 2 partial responses and stable disease in 3, and demonstrated increased efficacy over borussertib monotherapy (PMID: 30858154).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 9257,
                "therapyName": "Borussertib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 80199,
                "name": "colorectal carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12881,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients, however, there was no significant treatment-KRAS mutation interaction (p=0.24) (PMID: 29270615).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5781,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2723,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3437,
                    "pubMedId": 23475782,
                    "title": "Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23475782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6440,
            "approvalStatus": "Phase III",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a post-hoc analysis of a Phase III trial, KRAS mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that KRAS mutations may serve as a future prognostic biomarker in this patient population (PMID: 26768652).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 234,
                "name": "colon adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5600,
                    "pubMedId": 26768652,
                    "title": "Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26768652"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tarceva (erlotinib) and IRX4204 inhibited proliferation of non-small cell lung cancer cell lines in culture, including cell lines harboring KRAS mutations, and resulted in increased inhibition of proliferation and Src, p-AKT, and ribosomal S6 compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14095)).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5135,
                "therapyName": "Erlotinib + IRX4204",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9131,
                    "pubMedId": null,
                    "title": "IRX4204 in combination with erlotinib to target distinct pathways in lung cancer cells.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_192863.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11328,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cell lines harboring KRAS mutations, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5914,
                "therapyName": "AZD4785",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9180,
                    "pubMedId": 28615361,
                    "title": "Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28615361"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8389,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2768,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3465,
                    "pubMedId": 24935174,
                    "title": "Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24935174"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17501,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTI-31 inhibited proliferation and migration of a non-small cell lung cancer cell line harboring an oncogenic KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 8516,
                "therapyName": "MTI-31",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15515,
                    "pubMedId": 30796032,
                    "title": "A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30796032"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6132,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 957,
                "therapyName": "Volasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5317,
                    "pubMedId": 26597303,
                    "title": "Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26597303"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6698,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9388,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5002,
                "therapyName": "Linsitinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11971,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9382,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4996,
                "therapyName": "SCH772984 + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10258,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9376,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4988,
                "therapyName": "SCH772984 + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20578,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LY3009120 did not achieve expected pharmacodynamic effects, resulted in stable disease as best overall response in 2 of 17 patients with advanced or metastatic cancer harboring KRAS mutations (PMID: 31645440; NCT02014116).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17943,
                    "pubMedId": 31645440,
                    "title": "A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31645440"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6129,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 676,
                "therapyName": "BI2536",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5317,
                    "pubMedId": 26597303,
                    "title": "Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26597303"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6405,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5557,
                    "pubMedId": 27016228,
                    "title": "Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27016228"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2446,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2633,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Ramucirumab",
                "synonyms": "Ramucirumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2667,
                    "pubMedId": 25877855,
                    "title": "Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25877855"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10762,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 24% (6/25, all partial responses), and stable disease in 36% (9/25) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 18% (4/22) in patients with wild-type or unknown KRAS status (PMID: 27876675).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1264,
                "therapyName": "Docetaxel + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8810,
                    "pubMedId": 27876675,
                    "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9784,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5228,
                "therapyName": "NS1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7600,
                    "pubMedId": 27820802,
                    "title": "Inhibition of RAS function through targeting an allosteric regulatory site.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27820802"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2743,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3449,
                    "pubMedId": 19372556,
                    "title": "KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19372556"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 359,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1018,
                "therapyName": "GI-4000",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5728,
                    "pubMedId": 25044103,
                    "title": "Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25044103"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9387,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5001,
                "therapyName": "Panobinostat + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8732,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 841,
                "therapyName": "OSI-027",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3483,
                    "pubMedId": 21673091,
                    "title": "Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21673091"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11696,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6693,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7230,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 endometrial cancer patient harboring harboring KRAS mutation, who remained on treatment for over 456 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9379,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5004,
                "therapyName": "Pictilisib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9370,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and BVD-523 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4987,
                "therapyName": "AZD8186 + Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5621,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) combination treatment resulted in objective response in PDX models of colorectal cancer cells harboring KRAS mutations (PMID: 26369631).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5128,
                    "pubMedId": 26369631,
                    "title": "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26369631"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3354,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3760,
                    "pubMedId": 25605843,
                    "title": "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25605843"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14943,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of KRAS mutant colorectal cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13016,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1577,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 421,
                    "pubMedId": null,
                    "title": "Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.",
                    "url": "https://mct.aacrjournals.org/content/12/11_Supplement/C146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19305,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, treatment with Selumetinib (AZD6244) combined with Taxotere (docetaxel) did not result in an improved overall response rate in patients with gastric adenocarcinoma harboring a KRAS mutation versus patients with wild-type KRAS (36.4%, 4/11 vs 21.4%, 3/14; P=0.538) (PMID: 31315834).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1117,
                "therapyName": "Docetaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 16917,
                    "pubMedId": 31315834,
                    "title": "Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31315834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 748,
                "therapyName": "GDC-0623",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 187,
                    "pubMedId": 23934108,
                    "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23934108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11967,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13932,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived xenograft (PDX) models of colorectal cancer harboring KRAS, NRAS or BRAF mutations demonstrated poor response to SYM004 treatment compared to wild-type models (PMID: 29423521).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 931,
                "therapyName": "SYM004",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11366,
                    "pubMedId": 29423521,
                    "title": "Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29423521"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13887,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Simtuzumab (GS-6634) with FOLFIRI did not improve median progression-free survival (5.5 vs 5.8 months) or median overall survival (11.4 vs 16.3 months) compared to FOLFIRI with placebo in patients with KRAS mutant colorectal cancer (PMID: 28246207; NCT01479465).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1704,
                "therapyName": "Fluorouracil + Irinotecan + Leucovorin + Simtuzumab",
                "synonyms": "Simtuzumab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11330,
                    "pubMedId": 28246207,
                    "title": "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28246207"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7226,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2738,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3019,
                "therapyName": "Buparlisib + Tyrphostin B42",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3267,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3102,
                "therapyName": "Fluorouracil + Irinotecan + Oxaliplatin + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3703,
                    "pubMedId": 26341920,
                    "title": "Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26341920"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20588,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CV301 treatment was well-tolerated and resulted in a median progression-free survival (PFS) of 22 weeks in KRAS-mutant advanced solid tumor patients (n=6), which includes a pancreatic cancer patient with presumed KRAS mutation, compared to a PFS of 6 weeks in patients with wild-type KRAS (p=0.076) (PMID: 31110074; NCT02840994).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5243,
                "therapyName": "CV301",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17945,
                    "pubMedId": 31110074,
                    "title": "A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31110074"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6550,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3611,
                "therapyName": "TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10256,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10388,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8408,
                    "pubMedId": 27525386,
                    "title": "Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27525386"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11968,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13017,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 149,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 909,
                "therapyName": "Salirasib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 227,
                    "pubMedId": 21847063,
                    "title": "A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21847063"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7857,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4581,
                "therapyName": "Carboplatin + Erlotinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6514,
                    "pubMedId": 16043828,
                    "title": "Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16043828"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20384,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DFX117 treatment inhibited Pi3k/Akt and Met signaling, cell viability, and colony formation, and induced apoptosis and cell cycle arrest in a non-small lung carcinoma cell line harboring a KRAS mutation in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31060329).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 9339,
                "therapyName": "DFX117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17823,
                    "pubMedId": 31060329,
                    "title": "Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3K\u03b1 in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31060329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9397,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5010,
                "therapyName": "Saracatinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2013,
                "therapyName": "AZD8835",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4877,
                    "pubMedId": 26839307,
                    "title": "Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K\u03b1 and PI3K\u03b4, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26839307"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7741,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BATTLE-2), Selumetinib (AZD6244) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (49%, 24/49) and KRAS mutated (62%, 13/21) patients with advanced non-small cell lung carcinoma (PMID: 27480147; NCT01248247).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6464,
                    "pubMedId": 27480147,
                    "title": "The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480147"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11610,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination of Sprycel (dasatinib) and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma harboring KRAS codon 12/13 mutations, with no responses and a median time to treatment failure of 2.0 months (PMID: 28280091; NCT00501410).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6075,
                "therapyName": "Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Dasatinib + FOLFOX"
            },
            "indication": {
                "id": 50861,
                "name": "colorectal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9667,
                    "pubMedId": 28280091,
                    "title": "Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28280091"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5003,
                "therapyName": "Nilotinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9392,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5007,
                "therapyName": "BMS-754807 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7528,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients, most of whom harbored KRAS mutations (PMID: 26864210).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4505,
                "therapyName": "Ixabepilone + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6399,
                    "pubMedId": 26864210,
                    "title": "A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26864210"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9383,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4997,
                "therapyName": "MK2206 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KPT-185 resulted in greater apoptotic activity and decreased cell viability in non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations compared to NSCLC cell lines with wild-type KRAS, suggesting a synthetic lethal effect via XPO1 inhibition (PMID: 27680702).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4814,
                "therapyName": "KPT-185",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6758,
                    "pubMedId": 27680702,
                    "title": "XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27680702"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15050,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation was sensitive to the combination treatment of Selumetinib (AZD6244) and SHP099, demonstrating reduced cell viability and decreased colony formation in culture compared to either agent alone (PMID: 30045908).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4601,
                "therapyName": "Dasatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1287,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-847325 promoted tumor regression in mutant KRAS pancreatic adenocarcinoma models (Cancer Res 2012;72(8 Suppl):Abstract nr 1919).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 999,
                    "pubMedId": null,
                    "title": "Abstract 1919: Pharmacological characterization of BI 847325, a dual inhibitor of MEK and Aurora kinases",
                    "url": "http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/8_MeetingAbstracts/1919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9209,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with Luminespib (AUY922) in culture and in xenograft models (PMID: 26832792).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5083,
                    "pubMedId": 26832792,
                    "title": "Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832792"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1685,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1033,
                "therapyName": "MLN1117",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 1789,
                    "pubMedId": null,
                    "title": "Abstract 4501: INK1117: A potent and orally efficacious PI3Kalpha-selective inhibitor for the treatment of cancer",
                    "url": "http://cancerres.aacrjournals.org/content/71/8_Supplement/4501.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7367,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11973,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 2893,
                "name": "cervix carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2746,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Ipatasertib (GDC-0068) and Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Cancer Res, October 1, 2014 74; CT328).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1160,
                "therapyName": "Cobimetinib + Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1084,
                    "pubMedId": null,
                    "title": "Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT328.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2761,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3462,
                    "pubMedId": 22952903,
                    "title": "K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22952903"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7370,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2491,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708)",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2875,
                "therapyName": "MK2206 + Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3165,
                    "pubMedId": null,
                    "title": "Abstract 4708: Short-term romidepsin treatment combined with mitogen-activated protein kinase and phosphatidylinositol 3-kinase inhibition causes increased Bim expression and cell death in KRAS mutant cell lines",
                    "url": "http://cancerres.aacrjournals.org/content/72/8_Supplement/4708.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13940,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients harboring a KRAS mutation demonstrated an intermediate objective response rate (28.6% vs 35.7% vs 7.4%), PFS (2.7mo vs 3.0 vs 1.8), and OS (16.1mo vs 16.0 vs 6.4) compared to patients with co-occurring KRAS and TP53 mutations, and patients with co-occurring KRAS and STK11 mutations when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10458,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8465,
                    "pubMedId": 28152546,
                    "title": "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28152546"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11065,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2874,
                "therapyName": "CC-90003",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9060,
                    "pubMedId": null,
                    "title": "A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186986.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19937,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, borurssertib monotherapy did not result in tumor growth delay greater than controls in KRAS-mutant pancreatic ductal adenocarcinoma patient-derived xenograft (PDX) models (PMID: 30858154).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 9256,
                "therapyName": "Borussertib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12928,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "KRAS mutations are associated with shorter survival in patients with non-small cell lung carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3563,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3823,
                    "pubMedId": null,
                    "title": "677 Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease",
                    "url": "https://ash.confex.com/ash/2012/webprogram/Paper51144.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2740,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10963,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12882,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients, however, there was no significant treatment-KRAS mutation interaction (p=0.24) (PMID: 29270615).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11295,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 9220,
                    "pubMedId": 28039262,
                    "title": "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28039262"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9539,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1040,
                "therapyName": "Gedatolisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 220,
                    "pubMedId": 21325073,
                    "title": "Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21325073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10255,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19935,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of borussertib and Mekinist (trametinib) delayed tumor growth in KRAS-mutant pancreatic ductal adenocarcinoma patient-derived xenograft (PDX) models, and demonstrated increased efficacy over borussertib monotherapy (PMID: 30858154).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 9257,
                "therapyName": "Borussertib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17595,
                    "pubMedId": 30858154,
                    "title": "Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30858154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2762,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3024,
                "therapyName": "Pictilisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3462,
                    "pubMedId": 22952903,
                    "title": "K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22952903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5000,
                "therapyName": "Ralimetinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8018,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4620,
                "therapyName": "APS-2-79 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6534,
                    "pubMedId": 27556948,
                    "title": "Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27556948"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2719,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 666,
                "therapyName": "BAY1082439",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3435,
                    "pubMedId": null,
                    "title": "Activity of BAY1082439, a balanced PI3Kalpha/beta inhibitor, in gastric cancer",
                    "url": "http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=14323955-7e99-4856-aec7-b2f95e96b99b&cKey=5384c5ef-c9a4-49da-a50c-67bf77ceef19&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9380,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4994,
                "therapyName": "AZD8055 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10253,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2839,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2314,
                    "pubMedId": 21306821,
                    "title": "Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21306821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10967,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8965,
                    "pubMedId": null,
                    "title": "KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics",
                    "url": "http://www.ejcancer.com/article/S0959-8049(16)32974-4/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9001,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6848,
                    "pubMedId": 27422710,
                    "title": "Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422710"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7430,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2751,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3454,
                    "pubMedId": 24947927,
                    "title": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24947927"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11389,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10263,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2436,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3050,
                    "pubMedId": 25294897,
                    "title": "A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25294897"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15076,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Refametinib (BAY86-9766) and Nexavar (sorafenib) combination treatment resulted in an objective response rate of 6.3% (1/16), a disease control rate of 43.8% (7/16), an overall survival of 12.7 months, and a progression-free survival of 1.5 months in patients unresectable or metastatic hepatocellular carcinoma harboring RAS (NRAS and KRAS) mutations (PMID: 29950351; NCT01915602).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2221,
                "therapyName": "Refametinib + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12624,
                    "pubMedId": 29950351,
                    "title": "Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29950351"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 358,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 24372276, PMID: 25585100).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1018,
                "therapyName": "GI-4000",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 193,
                    "pubMedId": 24372276,
                    "title": "GI-4000 in KRAS mutant cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24372276"
                },
                {
                    "id": 5729,
                    "pubMedId": 25585100,
                    "title": "Pancreatic cancer, treatment options, and GI-4000.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25585100"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15663,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial (PREVIUM), Stivarga (regorafenib) treatment resulted in 0% (0/15) 6-month progression free survival (PFS), a 2.2-month median PFS, and a median overall survival of 3.3 months in metastatic colorectal cancer patients with KRAS (n=9), NRAS (n=3) or BRAF (n=2) mutations who failed first line therapy; however, the trial was terminated early due to poor accrual (PMID: 30120161; NCT02175654).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13568,
                    "pubMedId": 30120161,
                    "title": "Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30120161"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6004,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CONSIGN), Stivarga (regorafenib) treatment demonstrated safety profile and efficacy consistent with previous studies, median progression-free survival (PFS) was 2.7 months overall, 2.8 months in KRAS wild-type, and 2.5 months in KRAS mutant colorectal cancer patients, and with no difference in KRAS status between long and short PFS groups (PMID: 30190299; NCT01538680).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13521,
                    "pubMedId": 30190299,
                    "title": "Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30190299"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6670,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) treatment in a patient with metastatic colorectal cancer (PMID: 24304820).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 247,
                    "pubMedId": 24304820,
                    "title": "Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24304820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9378,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4992,
                "therapyName": "Everolimus + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9783,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5230,
                "therapyName": "Aurora Kinase Inhibitor II",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7603,
                    "pubMedId": 26842935,
                    "title": "Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26842935"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7373,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4479,
                "therapyName": "BGJ398 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9395,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5009,
                "therapyName": "Ipatasertib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1655,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Alpelisib (BYL719), in combination with Binimetinib (MEK162), demonstrated safety and preliminary efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1765,
                    "pubMedId": null,
                    "title": "A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/129278-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7374,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) demonstrated additive effect at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4480,
                "therapyName": "Crizotinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7368,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4477,
                "therapyName": "Ponatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10257,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9398,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5011,
                "therapyName": "Neratinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PD-0325901 to treatment with BEZ235 inhibited BEZ235-enhanced ERK activation, and the combination resulted in increased inhibition of cell proliferation in KRAS-mutant pancreatic ductal adenocarcinoma cell lines in culture compared to either agent alone (PMID: 25673820).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5162,
                "therapyName": "BEZ235 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3463,
                    "pubMedId": 25673820,
                    "title": "Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6732,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4074,
                "name": "pancreatic adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7375,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4481,
                "therapyName": "Gefitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6688,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7376,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4482,
                "therapyName": "Afatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2766,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PD-0325901 to treatment with GDC-0980 and inhibited GDC-0980-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic cancer cells harboring KRAS mutations in culture (PMID: 25673820).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3026,
                "therapyName": "GDC-0980 + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3463,
                    "pubMedId": 25673820,
                    "title": "Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12880,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, compared to Taxotere (docetaxel), treatment with immune checkpoint inhibitors including Opdivo (nivolumab), Keytruda (pembrolizumab), or Tecentriq (atezolizumab), resulted in prolonged overall survival in KRAS mutant (HR=0.65, P=0.03) but not KRAS wild-type (HR=0.86, P=0.24) non-small cell lung carcinoma patients, however, there was no significant treatment-KRAS mutation interaction (p=0.24) (PMID: 29270615).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10827,
                    "pubMedId": 29270615,
                    "title": "Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29270615"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13943,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated an objective response rate (ORR) of 18.2% (2/11) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation (PMID: 29773717; NCT01673867).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4617,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3552,
                "therapyName": "SH-1242",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4627,
                    "pubMedId": 26645561,
                    "title": "Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9369,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4986,
                "therapyName": "AZD8186 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1695,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1765,
                    "pubMedId": null,
                    "title": "A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/129278-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7372,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4478,
                "therapyName": "AZD4547 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5008,
                "therapyName": "Midostaurin + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6211,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMT-1536 induced tumor regression in patient-derived-xenograft models of of non-small cell lung cancer harboring KRAS mutations (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4094,
                "therapyName": "XMT-1536",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5466,
                    "pubMedId": null,
                    "title": "Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=43ef76fe-c845-4b4b-8531-601f2b1c2c32&cKey=132d0ba9-cd0a-4831-b61a-3bba3ae06518&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7739,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BATTLE-2), Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147; NCT01248247).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6464,
                    "pubMedId": 27480147,
                    "title": "The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480147"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13015,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9377,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4991,
                "therapyName": "Ridaforolimus + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12190,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6337,
                "therapyName": "LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6733,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12614,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Duligotuzumab (MEHD7945A) and Cotellic (cobimetinib) combination therapy demonstrated limited safety and efficacy, with stable disease as best response in 41% (9/22) of patients with KRAS-mutant solid tumors (PMID: 28592615; NCT01986166).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1342,
                "therapyName": "Cobimetinib + Duligotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10480,
                    "pubMedId": 28592615,
                    "title": "A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28592615"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6735,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8993,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6848,
                    "pubMedId": 27422710,
                    "title": "Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27422710"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12195,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6338,
                "therapyName": "Cetuximab + LSN3074753",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10143,
                    "pubMedId": 28611205,
                    "title": "Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6549,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3743,
                "therapyName": "Paclitaxel + TVB-2640",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5694,
                    "pubMedId": null,
                    "title": "Preliminary activity in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_166391.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17309,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, LXH 254 treatment resulted in partial response in 2.6% (2/75) and stable disease in 33% (25/75) of patients with advanced solid tumors harboring MAPK pathway alterations, one of the patient achieved partial response harbored a KRAS mutation (J Clin Oncol 36, no. 15_suppl (May 20 2018) 2586-2586; NCT02607813).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4442,
                "therapyName": "LXH 254",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15361,
                    "pubMedId": null,
                    "title": "A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2586"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9391,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5006,
                "therapyName": "Saracatinib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10262,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, primary tumor cells isolated from lung adenocarcinoma patients harboring KRAS mutations demonstrated increased sensitivity to Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment in culture compared to cells lacking KRAS or BRAF mutations (PMID: 26140595).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5443,
                "therapyName": "PF-00477736 + PF3644022",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8232,
                    "pubMedId": 26140595,
                    "title": "A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26140595"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 800,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 667,
                "therapyName": "Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 454,
                    "pubMedId": 23828442,
                    "title": "KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23828442"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2741,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3448,
                    "pubMedId": 19018267,
                    "title": "KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19018267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2748,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Rigosertib (ON 01910.Na) in combination with gemcitabine did not improve efficacy over gemcitabine alone, and there was no correlation of response with Kras mutational status in pancreatic patients (PMID: 26091808).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3021,
                "therapyName": "Gemcitabine + Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3452,
                    "pubMedId": 26091808,
                    "title": "A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26091808"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7233,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1343,
                "therapyName": "Atezolizumab + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6232,
                    "pubMedId": null,
                    "title": "Safety and efficacy of cobimetinib (cobi) and atezolizumab (atezo) in a Phase 1b study of metastatic colorectal cancer (mCRC)",
                    "url": "http://annonc.oxfordjournals.org/content/27/suppl_2/ii140.1.full"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 589,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1031,
                "therapyName": "Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 342,
                    "pubMedId": 23877793,
                    "title": "K\u2011ras gene mutation as a predictor of cancer cell responsiveness to metformin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23877793"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14053,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cancer cell lines harboring KRAS mutations demonstrated increased sensitivity to RAF709 compared to KRAS wild-type cells in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9381,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4995,
                "therapyName": "OSI-027 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 893,
                "therapyName": "Reolysin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8908,
                    "pubMedId": 24798549,
                    "title": "Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24798549"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9390,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5005,
                "therapyName": "PF-04691502 + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 150,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1117,
                "therapyName": "Docetaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 542,
                    "pubMedId": 23200175,
                    "title": "Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23200175"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9320,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) did not significantly improve median progression-free survival (3.9 vs 2.8 months), median overall survival (8.7 vs 7.9 months), and overall response rate (20.1% vs 13.7%) compared to placebo in KRAS-mutant non-small cell lung cancer patients (PMID: 28492898; NCT01933932).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1117,
                "therapyName": "Docetaxel + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8947,
                    "pubMedId": 28492898,
                    "title": "Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28492898"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1435,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 445,
                    "pubMedId": 22805291,
                    "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1436,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1067,
                    "pubMedId": 20664172,
                    "title": "Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664172"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7742,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BATTLE-2), Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147; NCT01248247).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 6464,
                    "pubMedId": 27480147,
                    "title": "The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480147"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7714,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (MISSION) trial, treatment with Nexavar (sorafenib) resulted in improved progression-free survival (PFS) in both KRAS-mutant (2.6 vs 1.7 mo, HR=0.46, p=0.007) and KRAS wild-type (2.7 vs 1.4 mo, HR=0.58, p<0.001) patients with non-small cell lung cancer when compared to placebo, however, overall survival (OS) was similar between the two arms, and biomarker treatment interaction analysis indicated no interaction between KRAS and PFS (p=0.696) or OS (p=0.743) (PMID: 26743856; NCT00863746).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 6454,
                    "pubMedId": 26743856,
                    "title": "Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743856"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2489,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 3164,
                    "pubMedId": 23224737,
                    "title": "A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23224737"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 204,
                    "pubMedId": 22781553,
                    "title": "AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22781553"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6700,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11974,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, two non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 445,
                    "pubMedId": 22805291,
                    "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7520,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13018,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "KRAS mutations are associated with lack of efficacy with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) in patients with non-small cell lung cancer (NCCN.org).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9384,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4998,
                "therapyName": "Navitoclax + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4999,
                "therapyName": "Danusertib + SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10058,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5359,
                "therapyName": "AZ-TAK1",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6701,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17370,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3214996 and LY3009120 synergistically inhibited proliferation of KRAS-mutant non-small cell lung cancer cell lines in culture (AACR Annual Meeting 2019, Abstract LB-083).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 8468,
                "therapyName": "LY3009120 + LY3214996",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15395,
                    "pubMedId": null,
                    "title": "Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9241"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10059,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5360,
                "therapyName": "AZ-TAK1 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7992,
                    "pubMedId": 27655129,
                    "title": "MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27655129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1690,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 induced apoptosis and cell cycle arrest in several human solid tumor and hematological cancer cell lines in culture and inhibited tumor growth in tumor cell line xenograft models, including those harboring KRAS mutations (PMID: 22693356).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2755,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3023,
                "therapyName": "Pimasertib + SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3459,
                    "pubMedId": null,
                    "title": "Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-147.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4369,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3498,
                "therapyName": "Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin",
                "synonyms": "Necitumumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4508,
                    "pubMedId": 26766738,
                    "title": "Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766738"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9371,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17369,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3214996 and LY3009120 synergistically inhibited proliferation of KRAS-mutant colorectal cancer cell lines in culture (AACR Annual Meeting 2019, Abstract LB-083).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 8468,
                "therapyName": "LY3009120 + LY3214996",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15395,
                    "pubMedId": null,
                    "title": "Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9241"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1627,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 445,
                    "pubMedId": 22805291,
                    "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16464,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS mutations correlated with resistance to Xalkori (crizotinib) in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2750,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3454,
                    "pubMedId": 24947927,
                    "title": "Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24947927"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11969,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12216,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cell lines harboring RAS mutations, including KRAS-mutant cell lines, demonstrated decreased sensitivity to growth inhibition by PI-273 in culture (PMID: 28827373).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 6363,
                "therapyName": "PI-273",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10169,
                    "pubMedId": 28827373,
                    "title": "PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KII\u03b1, Inhibits the Growth of Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28827373"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of KRAS mutant thyroid cancer cells in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16463,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRAS mutations correlated with resistance to TAE684 in patient-derived acute myeloid leukemia samples in an ex vivo assay (PMID: 30333627).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14523,
                    "pubMedId": 30333627,
                    "title": "Functional genomic landscape of acute myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30333627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9396,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3024,
                "therapyName": "Pictilisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7128,
                    "pubMedId": 26725216,
                    "title": "Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26725216"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8377,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Dinaciclib (SCH 727965) and MK-2206 inhibited tumor growth and metastasis in KRAS-mutant patient-derived xenograft models of pancreatic ductal adenocarcinoma, with some models achieving complete response (PMID: 25931518).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2193,
                "therapyName": "Dinaciclib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3366,
                    "pubMedId": 25931518,
                    "title": "Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25931518"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2725,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BI-847325 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Mol Cancer Ther 2013;12(11 Suppl):B281).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 998,
                    "pubMedId": null,
                    "title": "Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/B281.meeting_abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of combination PD-0325901 to treatment with Gedatolisib (PF-05212384) and PD-0325901 inhibited Gedatolisib (PF-05212384)-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic ductal adenocarcinoma cell lines harboring KRAS mutations in culture (PMID: 25673820).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 3025,
                "therapyName": "Gedatolisib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3463,
                    "pubMedId": 25673820,
                    "title": "Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7232,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 non-small cell lung carcinoma patient harboring KRAS mutation, who remained on treatment for over 572 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10765,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate (ORR) of 17% (4/23, all partial responses), and stable disease in 48% (11/23) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 11% (2/19) in patients with wild-type or unknown KRAS status (PMID: 27876675).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1266,
                "therapyName": "Pemetrexed + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8810,
                    "pubMedId": 27876675,
                    "title": "A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced\u00a0Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27876675"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14942,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Belvarafenib (HM95573) inhibited growth of KRAS mutant non-small cell lung cancer cells in culture and in cell line xenograft models (Cancer Res 2015;75(15 Suppl):Abstract nr 2607).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11830,
                    "pubMedId": null,
                    "title": "Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7740,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BATTLE-2), Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147; NCT01248247).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1097,
                "therapyName": "Erlotinib + MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6464,
                    "pubMedId": 27480147,
                    "title": "The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480147"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11970,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a pancreatic cancer patient harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 445,
                    "pubMedId": 22805291,
                    "title": "Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805291"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2844,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1867,
                "therapyName": "Deguelin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3500,
                    "pubMedId": 20811676,
                    "title": "Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20811676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9931,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 5315,
                "therapyName": "CGM097 + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2835,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9930,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 5314,
                "therapyName": "CGM097 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8388,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 865,
                "therapyName": "PF-04691502",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 226,
                    "pubMedId": 21750219,
                    "title": "PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21750219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2722,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 245,
                    "pubMedId": 24170767,
                    "title": "BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24170767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2840,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1018,
                    "pubMedId": 22693356,
                    "title": "Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22693356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2864,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 2448,
                "therapyName": "A-443654",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 962,
                    "pubMedId": 24978597,
                    "title": "Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24978597"
                },
                {
                    "id": 3512,
                    "pubMedId": 24569089,
                    "title": "Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24569089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2779,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 204,
                    "pubMedId": 22781553,
                    "title": "AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22781553"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 983,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11446,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9393,
                    "pubMedId": 28331003,
                    "title": "Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28331003"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 989,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20451,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI9322/PHL86) trial, Cometriq (Cabometyx, cabozantinib) treatment resulted in a response rate of 25% (3/12) and a 12-week progression-free survival rate of 83% (10/12) in patients with endometrial cancer harboring concurrent KRAS and PTEN or PIK3CA mutations, with a median PFS of 5.9 months (PMID: 31992589; NCT01935934).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17845,
                    "pubMedId": 31992589,
                    "title": "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31992589"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2795,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 2561,
                "therapyName": "AZD8055 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3482,
                    "pubMedId": 22271687,
                    "title": "Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22271687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2855,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 750,
                "therapyName": "GDC-0980",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3508,
                    "pubMedId": 21998291,
                    "title": "GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21998291"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3447,
                    "pubMedId": 22159814,
                    "title": "NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22159814"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2724,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3437,
                    "pubMedId": 23475782,
                    "title": "Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23475782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2851,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3507,
                    "pubMedId": null,
                    "title": "Abstract 915: Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/915.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9817,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous non-small cell lung cancer had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7642,
                    "pubMedId": 26098748,
                    "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26098748"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2874,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1145,
                    "pubMedId": 24608574,
                    "title": "Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24608574"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 145,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance (PMID: 20664172, PMID: 20664174).",
            "molecularProfile": {
                "id": 1630,
                "profileName": "KRAS mut PIK3CA mut"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 219,
                    "pubMedId": 20664174,
                    "title": "PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664174"
                },
                {
                    "id": 1067,
                    "pubMedId": 20664172,
                    "title": "Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8094,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1443,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 1773,
                "therapyName": "ABT-737 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1293,
                    "pubMedId": 21468686,
                    "title": "Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21468686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8140,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 4639,
                "therapyName": "Irinotecan + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 5319,
                "therapyName": "Alpelisib + CGM097 + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17730,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR405838 and Pimasertib (MSC1936369B) combination therapy demonstrated safety and preliminary efficacy, resulted in partial response in 4% (1/24) and stable disease in 63% (15/24) of patients with TP53 wild-type advanced solid tumors harboring RAS/RAF mutations (KRAS, n=24; BRAF, n=1; NRAS, n=1) (PMID: 30585255; NCT01985191).",
            "molecularProfile": {
                "id": 2521,
                "profileName": "KRAS mut TP53 wild-type"
            },
            "therapy": {
                "id": 8599,
                "therapyName": "Pimasertib + SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15755,
                    "pubMedId": 30585255,
                    "title": "A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30585255"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1462,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).",
            "molecularProfile": {
                "id": 2563,
                "profileName": "GATA2 wild-type KRAS mut"
            },
            "therapy": {
                "id": 1778,
                "therapyName": "Bortezomib + Fasudil",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1329,
                    "pubMedId": 22541434,
                    "title": "The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22541434"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) prevented cell growth and inhibited MTORC1 and MTORC2 signaling in rapamycin-resistant breast cancer cells harboring mutations in BRAF, CDKN2A, KRAS,NF2 and TP53 (PMID: 25261369).",
            "molecularProfile": {
                "id": 5003,
                "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2380,
                    "pubMedId": 25261369,
                    "title": "Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25261369"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3869,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15449,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CA225-025), Erbitux (cetuximab) treatment did not improve overall survival (HR=0.98, p=0.89) and progression-free survival (HR=0.99, p=0.96) compared to supportive care in patients with EGFR-positive, KRAS-mutant colorectal cancer who were refractory or intolerant of chemotherapy (PMID: 18946061; NCT00079066).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13328,
                    "pubMedId": 18946061,
                    "title": "K-ras mutations and benefit from cetuximab in advanced colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18946061"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15451,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CRYSTAL), the combination of Erbitux (cetuximab) and FOLFIRI did not improve progression-free survival (HR=1.07, p=0.75), progression-free survival (7.6 vs 8.1 months), and overall survival (HR=1.03) compared to FOLFIRI alone in patients with EGFR positive, KRAS-mutant colorectal cancer (PMID: 19339720; NCT00154102).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 2180,
                "therapyName": "Cetuximab + Fluorouracil + Irinotecan + Leucovorin",
                "synonyms": "Cetuximab + FOLFIRI"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10458,
                    "pubMedId": 19339720,
                    "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19339720"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3868,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3870,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16548,
                "profileName": "EGFR pos KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3866,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 4625,
                "therapyName": "Cisplatin + ER2",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5133,
                    "pubMedId": 27040853,
                    "title": "ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27040853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3865,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3867,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",
            "molecularProfile": {
                "id": 16550,
                "profileName": "EGFR dec exp KRAS mut"
            },
            "therapy": {
                "id": 3154,
                "therapyName": "GA201",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3814,
                    "pubMedId": 23209031,
                    "title": "GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23209031"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4055,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 treatment did not affect cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture and therefore, provides no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification were sensitive to BEZ235 in culture, resulting in decreased phosphorylation of downstream signaling targets and reduced cell viability (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification were sensitive to Vistusertib (AZD2014) in culture, resulting in decreased phosphorylation of downstream signaling targets and reduced cell viability (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 treatment did not affect cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture and therefore, provides no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4051,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) resulted in increased phosphorylation of Akt and demonstrated a minimal effect on cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture, therefore resulting in no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4448,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CB-839 increased senstivity of KRAS-mutant pancreatic ductal carcinoma cells with NQO1-over expression to ARQ761 in culture, and CB-839 and ARQ761 in combination resulted in decreased tumor growth and extended median survival in NQO1-over expressing KRAS-mutant pancreatic ductal carcinoma cell line xenograft models (PMID: 26462257)",
            "molecularProfile": {
                "id": 18160,
                "profileName": "KRAS mut NQO1 over exp"
            },
            "therapy": {
                "id": 3517,
                "therapyName": "ARQ761 + CB-839",
                "synonyms": null
            },
            "indication": {
                "id": 3587,
                "name": "pancreatic ductal carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4555,
                    "pubMedId": 26462257,
                    "title": "Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by \u00df-lapachone.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26462257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4568,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4570,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10766,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",
            "molecularProfile": {
                "id": 18590,
                "profileName": "KRAS mut PIK3CA wild-type"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8454,
                    "pubMedId": 26439693,
                    "title": "Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26439693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4574,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4576,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4575,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18591,
                "profileName": "KRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4572,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4571,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4573,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",
            "molecularProfile": {
                "id": 18592,
                "profileName": "KRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 3548,
                "therapyName": "Buparlisib + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4619,
                    "pubMedId": 26715098,
                    "title": "Targeting the PI3K signaling pathway in KRAS mutant colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26715098"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13941,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated an objective response rate (ORR) of 0% (0/6) when treated with Opdivo (nivolumab) compared to an ORR of 57.1% (4/7) in patients co-harboring a KRAS mutation and TP53 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).",
            "molecularProfile": {
                "id": 20858,
                "profileName": "KRAS mut STK11 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13938,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and STK11 mutation demonstrated a lower objective response rate (7.4% vs 35.7% vs 28.6%) and shorter PFS (1.8mo vs 3.0 vs 2.7), and OS (6.4mo vs 16 vs 16.1) compared to patients with KRAS and TP53 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).",
            "molecularProfile": {
                "id": 20858,
                "profileName": "KRAS mut STK11 mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5398,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).",
            "molecularProfile": {
                "id": 20858,
                "profileName": "KRAS mut STK11 mut"
            },
            "therapy": {
                "id": 3857,
                "therapyName": "PKI-402",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5041,
                    "pubMedId": 20371716,
                    "title": "Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20371716"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5408,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 3861,
                "therapyName": "Phenformin + Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5053,
                    "pubMedId": 26574479,
                    "title": "Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26574479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10705,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to Adavosertib (MK-1775) compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775)5 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",
            "molecularProfile": {
                "id": 20861,
                "profileName": "KRAS mut STK11 inact mut"
            },
            "therapy": {
                "id": 4186,
                "therapyName": "Adavosertib + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5559,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",
            "molecularProfile": {
                "id": 21268,
                "profileName": "APC mut KDR R961W KRAS mut"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5105,
                    "pubMedId": 27004155,
                    "title": "KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27004155"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21629,
                "profileName": "BRAF V600E KRAS mut"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21629,
                "profileName": "BRAF V600E KRAS mut"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6690,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23670,
                "profileName": "BRAF mut CDKN2A mut KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",
            "molecularProfile": {
                "id": 25304,
                "profileName": "FGFR1 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25304,
                "profileName": "FGFR1 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7365,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25304,
                "profileName": "FGFR1 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7361,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Frs2 expression through shRNA knockdown in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25306,
                "profileName": "FRS2 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7362,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25308,
                "profileName": "FGFR2 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7363,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",
            "molecularProfile": {
                "id": 25309,
                "profileName": "FGFR3 dec exp KRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6325,
                    "pubMedId": 27338794,
                    "title": "A combinatorial strategy for treating KRAS-mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27338794"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7460,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13939,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated a greater objective response rate (35.7% vs 7.4% vs 28.6%), longer PFS (3.0mo vs 1.8 vs 2.7) and OS (16mo vs 6.4 vs 16.1) compared to patients with KRAS and STK11 mutations and patients with KRAS mutations only when treated with a PD-1 inhibitor (Nivolumab, n=146; Pembrolizumab, n=19) (PMID: 29773717).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 5316,
                "therapyName": "Alpelisib + Erlotinib + Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7782,
                    "pubMedId": 27659046,
                    "title": "High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27659046"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13942,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, non-small cell lung carcinoma patients co-harboring a KRAS mutation and TP53 mutation demonstrated an objective response rate (ORR) of 57.1% (4/7) when treated with Opdivo (nivolumab) compared to an ORR of 0% (0/6) in patients co-harboring a KRAS mutation and STK11 mutation and an ORR of 18.2% (2/11) in patients with mutant KRAS only (PMID: 29773717; NCT01673867).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11296,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262).",
            "molecularProfile": {
                "id": 25456,
                "profileName": "KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9220,
                    "pubMedId": 28039262,
                    "title": "Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28039262"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26062,
                "profileName": "BRAF mut KRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11390,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing Ppp2r1a (PMID: 28504649).",
            "molecularProfile": {
                "id": 27982,
                "profileName": "KRAS mut PPP2R1A over exp"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11391,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing Ppp2r1a (PMID: 28504649).",
            "molecularProfile": {
                "id": 27982,
                "profileName": "KRAS mut PPP2R1A over exp"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11397,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 failed to induce apoptosis, inhibit Mapk signaling and tumor growth in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A L198V (PMID: 28504649).",
            "molecularProfile": {
                "id": 27983,
                "profileName": "KRAS mut PPP2R1A L198V"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11395,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A L198V (PMID: 28504649).",
            "molecularProfile": {
                "id": 27983,
                "profileName": "KRAS mut PPP2R1A L198V"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11396,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 failed to induce apoptosis, inhibit Mapk signaling and tumor growth in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A K194R (PMID: 28504649).",
            "molecularProfile": {
                "id": 27984,
                "profileName": "KRAS mut PPP2R1A K194R"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11394,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A K194R (PMID: 28504649).",
            "molecularProfile": {
                "id": 27984,
                "profileName": "KRAS mut PPP2R1A K194R"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11392,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A E197K (PMID: 28504649).",
            "molecularProfile": {
                "id": 27985,
                "profileName": "KRAS mut PPP2R1A E197K"
            },
            "therapy": {
                "id": 5969,
                "therapyName": "DT-061",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11393,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MK2206 combination treatment inhibited Mapk signaling, induced apoptosis, resulted in tumor growth inhibition in cell line xenograft models of KRAS mutant lung cancer over expressing PPP2R1A E197K (PMID: 28504649).",
            "molecularProfile": {
                "id": 27985,
                "profileName": "KRAS mut PPP2R1A E197K"
            },
            "therapy": {
                "id": 1098,
                "therapyName": "MK2206 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9273,
                    "pubMedId": 28504649,
                    "title": "Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28504649"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11783,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 I255del and mutations in KRAS and MYC (PMID: 27998224).",
            "molecularProfile": {
                "id": 28230,
                "profileName": "KRAS mut MYC mut TP53 I255del"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11778,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Paraplatin (carboplatin) and Adavosertib (MK-1775) combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224).",
            "molecularProfile": {
                "id": 28237,
                "profileName": "KRAS mut TP53 G105C TP53 V157fs"
            },
            "therapy": {
                "id": 1194,
                "therapyName": "Adavosertib + Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9762,
                    "pubMedId": 27998224,
                    "title": "Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27998224"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to Adavosertib (MK-1775) and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",
            "molecularProfile": {
                "id": 28317,
                "profileName": "KRAS mut STK11 loss TP53 loss"
            },
            "therapy": {
                "id": 1725,
                "therapyName": "Adavosertib + Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9874,
                    "pubMedId": 28652249,
                    "title": "WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28652249"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13947,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, lung adenocarcinoma patients negative for CD274 and co-harboring a KRAS mutation and TP53 mutation treated with a PD-1 inhibitor demonstrated a greater objective response rate compared to CD274-negative patients harboring either mutant KRAS only or co-harboring a KRAS mutation and STK11 mutation, 30% (3/10) vs 5.9% (1/17) vs 5.3% (1/19), respectively (PMID: 29773717).",
            "molecularProfile": {
                "id": 29888,
                "profileName": "CD274 neg KRAS mut TP53 mut"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11373,
                    "pubMedId": 29773717,
                    "title": "STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29773717"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20452,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NCI9322/PHL86) trial, Cometriq (Cabometyx, cabozantinib) treatment resulted in a response rate of 25% (3/12) and a 12-week progression-free survival rate of 83% (10/12) in patients with endometrial cancer harboring concurrent KRAS and PTEN or PIK3CA mutations, with a median PFS of 5.9 months (PMID: 31992589; NCT01935934).",
            "molecularProfile": {
                "id": 35180,
                "profileName": "KRAS mut PTEN mut"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17845,
                    "pubMedId": 31992589,
                    "title": "Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago and California Consortia (NCI9322/PHL86).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31992589"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 448,
            "profileName": "KRAS mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1630,
            "profileName": "KRAS mut PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2521,
            "profileName": "KRAS mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2563,
            "profileName": "GATA2 wild-type KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2652,
            "profileName": "KRAS mut MED23 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5003,
            "profileName": "BRAF mut CDKN2A mut KRAS mut NF2 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11800,
            "profileName": "KRAS mut PIK3CA mut PTEN del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16548,
            "profileName": "EGFR pos KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16550,
            "profileName": "EGFR dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17139,
            "profileName": "KRAS mut RICTOR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18160,
            "profileName": "KRAS mut NQO1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18590,
            "profileName": "KRAS mut PIK3CA wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18591,
            "profileName": "KRAS mut PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18592,
            "profileName": "KRAS mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20858,
            "profileName": "KRAS mut STK11 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20861,
            "profileName": "KRAS mut STK11 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21268,
            "profileName": "APC mut KDR R961W KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21629,
            "profileName": "BRAF V600E KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23670,
            "profileName": "BRAF mut CDKN2A mut KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25304,
            "profileName": "FGFR1 dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25306,
            "profileName": "FRS2 dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25308,
            "profileName": "FGFR2 dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25309,
            "profileName": "FGFR3 dec exp KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25456,
            "profileName": "KRAS mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26062,
            "profileName": "BRAF mut KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27982,
            "profileName": "KRAS mut PPP2R1A over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27983,
            "profileName": "KRAS mut PPP2R1A L198V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27984,
            "profileName": "KRAS mut PPP2R1A K194R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27985,
            "profileName": "KRAS mut PPP2R1A E197K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28230,
            "profileName": "KRAS mut MYC mut TP53 I255del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28237,
            "profileName": "KRAS mut TP53 G105C TP53 V157fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28317,
            "profileName": "KRAS mut STK11 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29888,
            "profileName": "CD274 neg KRAS mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31495,
            "profileName": "BRAF V600X KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35180,
            "profileName": "KRAS mut PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}